Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

September 25, 2024

Study Completion Date

September 25, 2024

Conditions

Huntington DiseaseTardive Dyskinesia

Interventions

DRUG

LPM3770164 sustained release tablet

Single-dose of 30 mg of LPM3770164 sustained release tablet

Trial Locations (1)

Shanghai Mental Health Center, Shanghai

All Listed Sponsors

lead

Luye Pharma Group Ltd.

INDUSTRY